Search research articles
Contact Us
Filters
Showing results (41-50 of 83) with videos related to
Page
of 9
Sort By:
International Journal of Molecular Sciences
|
March 28, 2024
Surface Topography, Microbial Adhesion, and Immune Responses in Silicone Mammary Implant-Associated Capsular Fibrosis
Ines Schoberleitner, Leoni Baier, Michaela Lackner, et al.
Molecular Oncology
|
June 13, 2024
Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, et al.
BMC Cancer
|
November 8, 2018
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)
Gabriel Rinnerthaler, Simon Peter Gampenrieder, Andreas Petzer, et al.
NPJ Breast Cancer
|
August 7, 2025
Clinical impact of single-gene vs. panel sequencing in advanced HR + /HER2- breast cancer: insights and implications
Eva Valentina Klocker, Nina Dobrić, Ricarda Graf, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
November 14, 2023
Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
Kerstin Wimmer, Monika Sachet, Cristiano Ramos, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 6, 2020
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial
Peter C Dubsky, Christian F Singer, Daniel Egle, et al.
Breast Cancer Research : BCR
|
December 15, 2021
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
Simon Peter Gampenrieder, Gabriel Rinnerthaler, Christoph Tinchon, et al.
Breast (Edinburgh, Scotland)
|
February 17, 2020
Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT
Guenther G Steger, Daniel Egle, Rupert Bartsch, et al.
Wiener Klinische Wochenschrift
|
September 23, 2022
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
Gabriel Rinnerthaler, Christian Singer, Edgar Petru, et al.
Breast Cancer Research and Treatment
|
January 25, 2024
Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
Kerstin Wimmer, Dominik Hlauschek, Marija Balic, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 83) with videos related to
Sort By:
Page
of 9
International Journal of Molecular Sciences
|
March 28, 2024
Surface Topography, Microbial Adhesion, and Immune Responses in Silicone Mammary Implant-Associated Capsular Fibrosis
Ines Schoberleitner, Leoni Baier, Michaela Lackner, et al.
Molecular Oncology
|
June 13, 2024
Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, et al.
BMC Cancer
|
November 8, 2018
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)
Gabriel Rinnerthaler, Simon Peter Gampenrieder, Andreas Petzer, et al.
NPJ Breast Cancer
|
August 7, 2025
Clinical impact of single-gene vs. panel sequencing in advanced HR + /HER2- breast cancer: insights and implications
Eva Valentina Klocker, Nina Dobrić, Ricarda Graf, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
November 14, 2023
Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
Kerstin Wimmer, Monika Sachet, Cristiano Ramos, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 6, 2020
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial
Peter C Dubsky, Christian F Singer, Daniel Egle, et al.
Breast Cancer Research : BCR
|
December 15, 2021
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
Simon Peter Gampenrieder, Gabriel Rinnerthaler, Christoph Tinchon, et al.
Breast (Edinburgh, Scotland)
|
February 17, 2020
Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT
Guenther G Steger, Daniel Egle, Rupert Bartsch, et al.
Wiener Klinische Wochenschrift
|
September 23, 2022
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
Gabriel Rinnerthaler, Christian Singer, Edgar Petru, et al.
Breast Cancer Research and Treatment
|
January 25, 2024
Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
Kerstin Wimmer, Dominik Hlauschek, Marija Balic, et al.
Page
of 9